{"id":58620,"date":"2026-03-03T12:39:25","date_gmt":"2026-03-03T04:39:25","guid":{"rendered":"https:\/\/flcube.com\/?p=58620"},"modified":"2026-03-03T12:39:26","modified_gmt":"2026-03-03T04:39:26","slug":"hotgen-biotech-doses-first-patient-in-aa001-phase-ib-anti-a%ce%b2-mab-targets-early-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58620","title":{"rendered":"Hotgen Biotech Doses First Patient in AA001 Phase Ib \u2013 Anti\u2011A\u03b2 mAb Targets Early Alzheimer&#8217;s Disease"},"content":{"rendered":"\n<p><strong>Hotgen Biotech Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/688068:SHA\">SHA:\u202f688068<\/a>)<\/strong> announced <strong>first subject dosing<\/strong> in a <strong>Phase Ib clinical study<\/strong> for <strong>AA001<\/strong>, its <strong>anti\u2011amyloid beta (A\u03b2) monoclonal antibody<\/strong>, in <strong>Chinese patients with mild cognitive impairment (MCI) due to Alzheimer&#8217;s disease (AD)<\/strong> and <strong>mild AD dementia<\/strong>. The study follows successful completion of <strong>Phase Ia<\/strong> last year, advancing Hotgen&#8217;s <strong>optimized anti\u2011A\u03b2 therapeutic<\/strong> into <strong>early\u2011stage patient populations<\/strong> where disease\u2011modifying interventions may be most effective.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-milestone\">Clinical Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Hotgen Biotech Co., Ltd (SHA:\u202f688068)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>AA001 monoclonal antibody (mAb)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Amyloid beta (A\u03b2)<\/td><\/tr><tr><td><strong>Clinical Stage<\/strong><\/td><td>Phase Ib initiated (first patient dosed)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Mild cognitive impairment due to AD + mild AD dementia<\/td><\/tr><tr><td><strong>Prior Study<\/strong><\/td><td>Phase Ia completed (2025)<\/td><\/tr><tr><td><strong>Structural Design<\/strong><\/td><td>Optimized for enhanced efficacy and reduced adverse reactions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-design-features\">Strategic Design Features<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>AA001 Optimization<\/th><th>Clinical Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Enhanced Efficacy<\/strong><\/td><td>Optimized structural design<\/td><td>Improved A\u03b2 clearance<\/td><\/tr><tr><td><strong>Reduced Adverse Reactions<\/strong><\/td><td>Engineering modifications<\/td><td>Lower ARIA (amyloid\u2011related imaging abnormalities) risk vs. competitors<\/td><\/tr><tr><td><strong>Early\u2011Stage Focus<\/strong><\/td><td>MCI + mild AD population<\/td><td>Potential for greater disease\u2011modifying effect prior to irreversible neurodegeneration<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Early Intervention Strategy:<\/strong> Targeting <strong>MCI and mild AD<\/strong>\u2014vs. moderate\u2011to\u2011severe dementia\u2014aligns with <strong>Leqembi (Eisai\/Biogen)<\/strong> and <strong>Kisunla (Eli Lilly)<\/strong> approval paradigms, where <strong>earlier treatment<\/strong> demonstrates superior clinical outcomes.<\/li>\n\n\n\n<li><strong>Safety Differentiation:<\/strong> The <strong>optimized structural design<\/strong> aims to <strong>reduce ARIA\u2011E\/ARIA\u2011H<\/strong> (brain edema\/hemorrhage), the <strong>dose\u2011limiting toxicity<\/strong> of approved anti\u2011A\u03b2 antibodies, potentially enabling <strong>higher dosing<\/strong> and <strong>faster titration<\/strong>.<\/li>\n\n\n\n<li><strong>China Alzheimer&#8217;s Burden:<\/strong> China has the <strong>world&#8217;s largest AD population<\/strong> (~\u202f10\u202fmillion patients); domestic development addresses <strong>unmet medical need<\/strong> and <strong>regulatory preference<\/strong> for locally innovated therapies.<\/li>\n\n\n\n<li><strong>Diagnostic Synergy:<\/strong> Hotgen&#8217;s <strong>established IVD business<\/strong> (COVID\u201119 tests, infectious disease diagnostics) may support <strong>companion diagnostic development<\/strong> for patient selection and treatment monitoring.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Anti\u2011A\u03b2 Market<\/strong><\/td><td>~\u202f$5\u202fbillion by 2030; dominated by Leqembi and Kisunla with significant safety monitoring requirements<\/td><\/tr><tr><td><strong>China AD Market<\/strong><\/td><td>Rapidly growing with aging population; limited approved disease\u2011modifying therapies; strong demand for safer alternatives<\/td><\/tr><tr><td><strong>ARIA Risk Management<\/strong><\/td><td>ARIA occurs in ~\u202f12\u201115% of Leqembi patients; AA001&#8217;s optimized design may reduce incidence and severity<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Roche&#8217;s gantenerumab discontinued; donanemab (Lilly) approved; Hotgen&#8217;s Phase Ib positions for China\u2011first or global partnership<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase Ib enrollment, safety profile confirmation, and disease\u2011modifying potential for AA001. Actual results may differ due to risks including ARIA signals in larger cohorts, competitive anti\u2011A\u03b2 launches, and Alzheimer&#8217;s diagnostic infrastructure limitations in China.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688068_20260303_FXWA.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688068_20260303_FXWA.\"><\/object><a id=\"wp-block-file--media-1b208fe5-d1c8-4429-a2cf-d22fcd23e033\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688068_20260303_FXWA.pdf\">688068_20260303_FXWA<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688068_20260303_FXWA.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-1b208fe5-d1c8-4429-a2cf-d22fcd23e033\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hotgen Biotech Co., Ltd (SHA:\u202f688068) announced first subject dosing in a Phase Ib clinical study&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,420,1205],"class_list":["post-58620","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hotgen-biotech","tag-sha-688068"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hotgen Biotech Doses First Patient in AA001 Phase Ib \u2013 Anti\u2011A\u03b2 mAb Targets Early Alzheimer&#039;s Disease - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hotgen Biotech Co., Ltd (SHA:\u202f688068) announced first subject dosing in a Phase Ib clinical study for AA001, its anti\u2011amyloid beta (A\u03b2) monoclonal antibody, in Chinese patients with mild cognitive impairment (MCI) due to Alzheimer&#039;s disease (AD) and mild AD dementia. The study follows successful completion of Phase Ia last year, advancing Hotgen&#039;s optimized anti\u2011A\u03b2 therapeutic into early\u2011stage patient populations where disease\u2011modifying interventions may be most effective.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58620\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hotgen Biotech Doses First Patient in AA001 Phase Ib \u2013 Anti\u2011A\u03b2 mAb Targets Early Alzheimer&#039;s Disease\" \/>\n<meta property=\"og:description\" content=\"Hotgen Biotech Co., Ltd (SHA:\u202f688068) announced first subject dosing in a Phase Ib clinical study for AA001, its anti\u2011amyloid beta (A\u03b2) monoclonal antibody, in Chinese patients with mild cognitive impairment (MCI) due to Alzheimer&#039;s disease (AD) and mild AD dementia. The study follows successful completion of Phase Ia last year, advancing Hotgen&#039;s optimized anti\u2011A\u03b2 therapeutic into early\u2011stage patient populations where disease\u2011modifying interventions may be most effective.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58620\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-03T04:39:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-03T04:39:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58620#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58620\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hotgen Biotech Doses First Patient in AA001 Phase Ib \u2013 Anti\u2011A\u03b2 mAb Targets Early Alzheimer&#8217;s Disease\",\"datePublished\":\"2026-03-03T04:39:25+00:00\",\"dateModified\":\"2026-03-03T04:39:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58620\"},\"wordCount\":433,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Hotgen Biotech\",\"SHA: 688068\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58620#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58620\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58620\",\"name\":\"Hotgen Biotech Doses First Patient in AA001 Phase Ib \u2013 Anti\u2011A\u03b2 mAb Targets Early Alzheimer's Disease - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-03T04:39:25+00:00\",\"dateModified\":\"2026-03-03T04:39:26+00:00\",\"description\":\"Hotgen Biotech Co., Ltd (SHA:\u202f688068) announced first subject dosing in a Phase Ib clinical study for AA001, its anti\u2011amyloid beta (A\u03b2) monoclonal antibody, in Chinese patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia. The study follows successful completion of Phase Ia last year, advancing Hotgen's optimized anti\u2011A\u03b2 therapeutic into early\u2011stage patient populations where disease\u2011modifying interventions may be most effective.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58620#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58620\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58620#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hotgen Biotech Doses First Patient in AA001 Phase Ib \u2013 Anti\u2011A\u03b2 mAb Targets Early Alzheimer&#8217;s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hotgen Biotech Doses First Patient in AA001 Phase Ib \u2013 Anti\u2011A\u03b2 mAb Targets Early Alzheimer's Disease - Insight, China&#039;s Pharmaceutical Industry","description":"Hotgen Biotech Co., Ltd (SHA:\u202f688068) announced first subject dosing in a Phase Ib clinical study for AA001, its anti\u2011amyloid beta (A\u03b2) monoclonal antibody, in Chinese patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia. The study follows successful completion of Phase Ia last year, advancing Hotgen's optimized anti\u2011A\u03b2 therapeutic into early\u2011stage patient populations where disease\u2011modifying interventions may be most effective.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58620","og_locale":"en_US","og_type":"article","og_title":"Hotgen Biotech Doses First Patient in AA001 Phase Ib \u2013 Anti\u2011A\u03b2 mAb Targets Early Alzheimer's Disease","og_description":"Hotgen Biotech Co., Ltd (SHA:\u202f688068) announced first subject dosing in a Phase Ib clinical study for AA001, its anti\u2011amyloid beta (A\u03b2) monoclonal antibody, in Chinese patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia. The study follows successful completion of Phase Ia last year, advancing Hotgen's optimized anti\u2011A\u03b2 therapeutic into early\u2011stage patient populations where disease\u2011modifying interventions may be most effective.","og_url":"https:\/\/flcube.com\/?p=58620","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-03T04:39:25+00:00","article_modified_time":"2026-03-03T04:39:26+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58620#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58620"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hotgen Biotech Doses First Patient in AA001 Phase Ib \u2013 Anti\u2011A\u03b2 mAb Targets Early Alzheimer&#8217;s Disease","datePublished":"2026-03-03T04:39:25+00:00","dateModified":"2026-03-03T04:39:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58620"},"wordCount":433,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Hotgen Biotech","SHA: 688068"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58620#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58620","url":"https:\/\/flcube.com\/?p=58620","name":"Hotgen Biotech Doses First Patient in AA001 Phase Ib \u2013 Anti\u2011A\u03b2 mAb Targets Early Alzheimer's Disease - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-03T04:39:25+00:00","dateModified":"2026-03-03T04:39:26+00:00","description":"Hotgen Biotech Co., Ltd (SHA:\u202f688068) announced first subject dosing in a Phase Ib clinical study for AA001, its anti\u2011amyloid beta (A\u03b2) monoclonal antibody, in Chinese patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia. The study follows successful completion of Phase Ia last year, advancing Hotgen's optimized anti\u2011A\u03b2 therapeutic into early\u2011stage patient populations where disease\u2011modifying interventions may be most effective.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58620#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58620"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58620#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hotgen Biotech Doses First Patient in AA001 Phase Ib \u2013 Anti\u2011A\u03b2 mAb Targets Early Alzheimer&#8217;s Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58620","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58620"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58620\/revisions"}],"predecessor-version":[{"id":58622,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58620\/revisions\/58622"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58620"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58620"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58620"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}